Prospective randomized phase II trial for the treatment of patients with advanced hormone refractory prostate cancer using LHRH analogues and somatostatin analogues, as well as taking into account the expression of neuroendocrine Androgen receptor status [Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus]

Trial Profile

Prospective randomized phase II trial for the treatment of patients with advanced hormone refractory prostate cancer using LHRH analogues and somatostatin analogues, as well as taking into account the expression of neuroendocrine Androgen receptor status [Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2012

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms Soma47
  • Most Recent Events

    • 03 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top